Heartflow, Inc. · NASDAQ:HTFL
Heartflow — Longview Acquisition Corp. II — SPAC Merger (September 2021)
31 slides from Heartflow's SPAC merger presentation, Sep 15, 2021
Slide 1: Investor Presentation September 2021
Investor Presentation September 2021
Slide 2: Disclaimer
Disclaimer 2 Disclaimer This presentation is for information purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between HeartFlow Holding, Inc. (“HeartFlow”) and Longview Acquisition Corp. II (“Long
Slide 3: Disclaimer (continued)
Disclaimer (continued) 3 Industry and Market Data In this Presentation, Longview and HeartFlow rely on and refer to certain information and statistics obtained from third-party sources which they believe to be reliable. Neither Longview nor HeartFlow has independently verified the accuracy or comple
Slide 4: Transaction Overview
• Longview Acquisition Corp. II (“Longview II”) is a Special Purpose Acquisition Corporation (“SPAC”) brought public as an affiliate of Glenview Capital Management • Initially capitalized with $690 million in cash in trust in March 2021 trading under the ticker LGV • Glenview Capital was founded in
Slide 5: Transaction Overview
Transaction Overview Sources Equity to HeartFlow Stockholders $2,150.0 Longview Cash Held in Trust1 690.0 Pre-Closing Return of Capital1,2 (91.0) Total Sources2 $2,749.0 Uses Equity to HeartFlow Stockholders $2,150.0 Cash to Balance Sheet1,2 346.5 Cash for Secondary Purchases 110.0 Debt Retirement,
Slide 6: Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers
Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers 6 12
Slide 7: Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend
Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend Source: CDC Division for Heart Disease and Stroke Prevention, 2019; American Heart Association, 2017; Yelin et. al. 7 1 out of every 3 deaths Cardiovascular Disease Costs Will Exceed $1 Trillion by 2035, Warns the
Slide 8: The Status Quo Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing is Suboptimal
The “Status Quo” Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing is Suboptimal 8 Stress Echocardiography SPECT & PET Nuclear Scans Treadmill ECG Risk Assessment Non-invasive Testing 10M non-invasive tests in the US alone every year UNDETECTED DISEASE 20-30% FALSE NEGATIVES: Pat
Slide 9: Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers
Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers 9 12
Slide 10: HeartFlow Has Spent Over a Decade Solving the Technical, Business and Regulatory Challenges
2017 Commercial coverage began CMS engagement initiated Dec: Initiation of select coverage policies HeartFlow Has Spent Over a Decade Solving the Technical, Business and Regulatory Challenges Necessary to Unlock All Barriers to Adoption 2010 HeartFlow founded 2011 CE Mark obtained 2016 Japan PMDA Ap
Slide 11: Developed a Revolutionary Precision Heart Care Technology that Disrupts the Status Quo
CTA-based Fractional Flow Reserve (FFRCT) & Plaque1 Treatment Planning Myocardial Blood Flow2 11 HeartFlow Developed and Introduced a Revolutionary Precision “Heart Care” Technology that Disrupts the Status Quo HeartFlow’s product suite leverages and builds upon a foundational technology platform Pr
Slide 12: Empowering Physicians with an AI-enabled, Cloud-based Enterprise Software Suite
• AI-powered modeling of all coronary arteries • Highest diagnostic accuracy driven by big data analytics • Compliant cloud computing to protect sensitive data • Secure bi-directional data transmission to / from hospital IT systems ADVANCED TECH • Helps explain symptoms, providing peace-of-mind • Fe
Slide 13: Transforming Cardiovascular Disease Risk Assessment, Diagnosis, Planning, and Treatment Management
13 Risk Assessment (Prevention) Precision Diagnostics Optimization of Therapy Monitoring (Pre or Post Treatment) Risk Score for Asymptomatic Patients* PreRead* Plaque* Planner Medical Therapy Planning* CABG Planning* Stent & Bypass Graft Monitoring* FFRCT *Currently in development and not available
Slide 14: Delivering Precise, Personalized and Enhanced Care Decisions for Patients
14 Delivering Precise, Personalized and Enhanced Care Decisions for Patients Monitor Assess Diagnose Plan Treat Assess Diagnose Plan Monitor Treat 5 1 2 3 4 • The historical path to diagnosing CAD is unclear, unreliable, insufficient and ineffective • Patients and staff benefit from a "one stop, clo
Slide 15: AGE: 68. SEX: MALE HISTORY: ASYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE *Currently in development
15 15 AGE: 68. SEX: MALE HISTORY: ASYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE *Currently in development and not available for clinical use. AGE: 60 SEX: MALE HISTORY: SYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE *Currently in development and not available for clinical use.
Slide 16: Providing Significant Clinical Evidence
≫ 16 company-sponsored clinical trials and registries addressing accuracy and outcomes ≫ 100+ investigator-initiated studies ≫ 425+ peer-reviewed publications, including JAMA, JACC, Circulation, American Journal of Cardiology, European Heart Journal and Heart ≫ Studied in >10,000 patients ≫ Demonstr
Slide 17: Unmatched IP Portfolio Built on Years of Innovation
17 Unmatched IP Portfolio Built on 25 Years of Innovation 400+ Issued patents worldwide 2 Petabytes+ of Coronary Imaging Data 15 Million+ Annotated CT Images Expected to double in next 12 months Leveraging a Strong Intellectual Property Portfolio HeartFlow’s differentiated IP portfolio provides a po
Slide 18: Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers
Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers HeartFlow has unlocked key barriers to adoption of their technology offering 18 Technology & Healthcare Competency ü Experienced, diverse management team with relevant tech and cardiology backgrounds Clinical Eviden
Slide 19: Unlocked Barriers Driving Adoption: Recognized by Key Cardiology Societies
19 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers The CTA + HeartFlow pathway is recognized by key cardiology societies “Unless obstructive CAD can be excluded based on clinical evaluation alone, either non-invasive functional imaging or anatomical imaging using
Slide 20: System-Wide Adoption
20 System-Wide Adoption 1. Top 50 Heart Hospitals as designated by US News and World Report 2. Includes 71% coverage with local coverage determinations and 29% on a case-by-case basis 80% of the Top 50 Heart Hospitals1 in the US Have Adopted HeartFlow Large healthcare systems have initiated the adop
Slide 21: Equip clinicians with superior technology to deliver better healthcare while reducing costs
We believe the true way to deliver “better” healthcare while reducing costs is to equip clinicians with superior technology that fundamentally informs better care management decisions Universal Access Earlier Diagnosis & Intervention Value-Based Care Harnessing AI & Big Data Collaboration Through th
Slide 22: Predictable and Attractive SaaS Model Combining Fee-per-analysis and Base Subscription
Fee-per-analysis for delivery of FFRCT and Plaque1 22 • FFRCT • Plaque Comprehensive engagement with customer sites drives land, retain, and expand strategy Revenue Model Subscription provides access to bundle of advanced product features Products • PreRead • Myocardial Insights • Planner Products •
Slide 23: Augmented by a Robust Software Pipeline to Fuel a Significant TAM
23 Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow is developing a comprehensive, integrated cloud-based heart care technology product suite to help physicians make more optimal cardiovascular care decisions FFRCT Planner PreRead Myocardial Insights Plaque Analysis Anatom
Slide 24: From a fraction of a fraction to a majority of a majority
24 Augmented by a Robust Software Pipeline to Fuel a Significant TAM From a fraction of a fraction to a majority of a majority • Over the coming 15 years, we envision HeartFlow moving from a small minority of coronary CTA scans to being attached to the vast majority • Additionally, over the same per
Slide 25: Clear projected development path to grow TAM from $10B to $50B+
25 Asymptomatic / Preventative Today Near Term Medium Term Long Term FFRCT Fee Per Analysis $10.1B Symptomatic Total: $10.1B Total: $10.8B Total: $17.9B Total: $49.7B Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow has a clear projected development path to grow TAM from $
Slide 26: Fueling a Compelling High Growth Outlook: Key Growth Drivers
26 Fueling a Compelling High Growth Outlook 1. Anticipated ACC/AHA guidelines + CMS reimbursement changes that place CTA – FFRCT on par with SPECT 2. New customer site additions primarily in the US, the UK, and Japan 3. Increased utilization and attachment rate of FFRCT to CTA at current sites 4. La
Slide 27: Fueling a Compelling High Growth Outlook
$23 $36-$42 $92 $205 $345 $525 $0 $200 $400 $600 2020A 2021E 2022E 2023E 2024E 2025E 27 Fueling a Compelling High Growth Outlook Revenue ($ millions) 33% ~49+% ~69% ~78% ~82% ~85% 0% 20% 40% 60% 80% 100% 2020A 2021E 2022E 2023E 2024E 2025E Gross Margin 2021-2025 Plan +88% ’21E-’25E CAGR Management b
Slide 28: Led by a Strong Team
Charles A. Taylor, Ph.D.* Founder, Chief Technology Officer Stanford University, GE John Stevens, M.D.* President & CEO, Co-founder Heartport, Amp Resources, Stanford University Nicky Espinosa General Counsel, Chief Ethics and Compliance Officer Brobeck, Phleger & Harrison, Illumina, Intuitive Surgi
Slide 29: Fortified by Experienced Investment Partners
Fortified by Experienced Investment Partners 29 Existing HeartFlow Investor Base
Slide 30: Enabling Access to Optimized Care for All Patient Populations
Enabling Access to Optimized Care for All Patient Populations Unlock & Penetrate Significant TAM Expand & Enhance Access to Care Improve Quality of Care Reduce Cost Improve Diagnostic Accuracy Improve Patient Experience Disruptive, Best-in-class Non-invasive Precision Heart Care Robust Intellectual
Slide 31: Thank You!
Thank You! O HeartFlow’
Longview Acquisition Corp. II — SPAC Merger (September 2021) on 6ix